Sonnet Biotherapeutics Valuation
| SONN Stock | USD 2.79 0.19 6.38% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Sonnet Biotherapeutics has a current Real Value of $20.46 per share. The regular price of the company is $2.79. Our model measures the value of Sonnet Biotherapeutics from inspecting the company fundamentals such as Return On Equity of -2.65, current valuation of (907.92 K), and Shares Owned By Insiders of 4.22 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Sonnet Biotherapeutics' valuation include:
Price Book 0.9534 | Enterprise Value -907.9 K | Enterprise Value Ebitda (0.21) | Price Sales 44.6703 | Enterprise Value Revenue 35.9059 |
Undervalued
Today
Please note that Sonnet Biotherapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Sonnet Biotherapeutics is based on 3 months time horizon. Increasing Sonnet Biotherapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sonnet Biotherapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sonnet Stock. However, Sonnet Biotherapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.79 | Real 20.46 | Target 73.0 | Hype 3.99 | Naive 3.51 |
The intrinsic value of Sonnet Biotherapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sonnet Biotherapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sonnet Biotherapeutics Holdings helps investors to forecast how Sonnet stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sonnet Biotherapeutics more accurately as focusing exclusively on Sonnet Biotherapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Sonnet Biotherapeutics' intrinsic value based on its ongoing forecasts of Sonnet Biotherapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Sonnet Biotherapeutics' closest peers.
Sonnet Biotherapeutics Cash |
|
Sonnet Valuation Trend
Knowing Sonnet Biotherapeutics' actual value is paramount for traders when making sound investment determinations. Using both Sonnet Biotherapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Sonnet Revenue by Product
Sonnet Biotherapeutics Total Value Analysis
Sonnet Biotherapeutics Holdings is at this time estimated to have valuation of (907.92 K) with market capitalization of 2.5 M, debt of 203.91 K, and cash on hands of 5.22 M. The negative valuation of Sonnet Biotherapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Sonnet Biotherapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(907.92 K) | 2.5 M | 203.91 K | 5.22 M |
Sonnet Biotherapeutics Investor Information
The company has price-to-book ratio of 0.95. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sonnet Biotherapeutics recorded a loss per share of 0.96. The entity last dividend was issued on the 2nd of April 2020. The firm had 1:8 split on the 30th of September 2024. Based on the key indicators related to Sonnet Biotherapeutics' liquidity, profitability, solvency, and operating efficiency, Sonnet Biotherapeutics Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Sonnet Biotherapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sonnet Biotherapeutics has an asset utilization ratio of 2.72 percent. This suggests that the Company is making $0.0272 for each dollar of assets. An increasing asset utilization means that Sonnet Biotherapeutics Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Sonnet Biotherapeutics Ownership Allocation
Sonnet Biotherapeutics has 4.22 % of its outstanding shares held by insiders and 0.61 % owned by institutional holders.Sonnet Biotherapeutics Profitability Analysis
The company reported the previous year's revenue of 147.81 K. Net Loss for the year was (18.83 M) with loss before overhead, payroll, taxes, and interest of (21.09 M).About Sonnet Biotherapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Sonnet Biotherapeutics Holdings. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Sonnet Biotherapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Sonnet Biotherapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Sonnet Biotherapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Sonnet Biotherapeutics. We calculate exposure to Sonnet Biotherapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sonnet Biotherapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 32.7 M | 34.3 M | |
| Pretax Profit Margin | (0.26) | (0.28) | |
| Operating Profit Margin | (0.10) | (0.10) | |
| Net Loss | (0.22) | (0.23) | |
| Gross Profit Margin | 0.03 | 0.03 |
Sonnet Biotherapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1 M |
Sonnet Biotherapeutics Current Valuation Indicators
Sonnet Biotherapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Sonnet Biotherapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Sonnet Biotherapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Sonnet Biotherapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Sonnet Biotherapeutics' worth.When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.